Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAB-LA vs Oral PrEP for HIV Prevention in MSM
NCT06273943Phase 3Not yet recruiting
- Sponsor
- ANRS
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabotegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoint: Number of protocol visits completed with a documented PrEP prescription aligned with the randomization arm at Month 12. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06273943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273943.